Lisa Henderson

New Jersey

VP, Editorial at Informa

Editor for Applied Clinical Trials, covered IT, managed care, pharma in the past. Views are my own. Love my job!

Featured in: Favicon

pharmexec.com Favicon

appliedclinicaltrialsonline.com Favicon

pharmaceuticalcommerce.com Favicon

adweek.com Favicon

bizjournals.com Favicon

patch.com

sme.org

eastlondonlines.co.uk Favicon

informa.com Favicon

friendsofcancerresearch.org + 2 more

Articles

Rare disease therapeutic development facing challenges

1 month ago | informaconnect.com | Lisa Henderson

Industry experts point to a combination of factors negatively impacting the space, including IRA, funding and market access concerns. 2024 heralded many investment deals, as well as FDA approvals, in the rare disease space. For example, 26 of CDER’s 50 novel drug approvals (52%), were approved to treat rare or “orphan” diseases.
Complying with trial registries and other global disclosure reporting requirements an ongoing challenge

Jan 15, 2025 | informaconnect.com | Lisa Henderson

Registering clinical trials globally, along with the ever-multiplying regulatory document landscape, can lead to untenable oversight and compliance issues. Since the year 2000, approximately two new trial registries have opened each year.
Attention to PBM vertical integration will continue through 2025

Jan 8, 2025 | informaconnect.com | Lisa Henderson

In this article, we re-capped the top trends from the last three months of Access events from Informa Life Sciences. Our last trend was the vertical integration of PBMs, in this regard to the PBMs’ white labeling of biosimilars, further complicating the access professionals’ visibility into the supply chain. However, this is just one more example of PBM practices that have become a bridge too far.
2025: Continued chaos at the retail pharmacy level

Jan 7, 2025 | informaconnect.com | Lisa Henderson

Smack dab in the middle of the Trade & Channel Strategies conference last month, the Wall Street Journal reported that the Walgreen’s Boots Alliance (WBA) was discussing with private equity firm Sycamore Partners a potential sale that would bring the company private and off of the NASDAQ. While the news remains unconfirmed, industry watchers believe its scheduled January 10 earnings call could shed more light on the situation.
HOSP names new president

Jan 7, 2025 | informaconnect.com | Lisa Henderson

The Health System Owned Specialty Pharmacy Alliance (HOSP) has appointed Tim Affeldt, PharmD, vice president, Specialty/Infusion Operations for Fairview Pharmacy Services, as its new president. HOSP is a nationwide member-led organization of leading health systems that represents the interests of the health system owned specialty pharmacy industry. Partners of the organization include pharma companies.
Lackluster patient experiences in access programs

Nov 4, 2024 | informaconnect.com | Lisa Henderson

Programs developed for specialty medicines suffer from negative patient experiences, according to recent research. Recent poster abstracts peer reviewed by The Association of Managed Care Pharmacy included research on patient experience with specialty medicine alternative funding programs (AFPs), variations in payer prior authorization rates, and patient experience data in payer decision-making.
Common pitfalls in 340B audits (and how to avoid them)

Oct 21, 2024 | informaconnect.com | Lisa Henderson

At the recent Medicaid Drug Rebate Program (MDRP) Summit, officials from the HRSA Office of Pharmacy Affairs, Office of Special Health Initiatives shared the common pitfalls that manufacturers make that show up in 340B audits. Julie Zadecky, pharmacist, Office of Pharmacy Affairs, Office of Special Health Initiatives, listed the most frequent audit findings they gathered on data from the past five years. She then described them and offered risk mitigation strategies.
State of the states

Oct 11, 2024 | informaconnect.com | Lisa Henderson

A recent webinar from IQVIA Institute, “Health Policy Forum: Policy Priorities for the Next U.S. Administration,” discussed policy change at the state level that could potentially effect the larger access audience.
CAAP bans benefit patients

Oct 11, 2024 | informaconnect.com | Lisa Henderson

A recent study sheds light on the effectiveness of state legislation banning copay accumulator adjustment programs (CAAPs) in state-regulated health plans. The research, which the authors say is the first to assess real-world implications of state legislation prohibiting the use of CAAPs for state-regulated health plans, reveals a significant correlation between CAAP bans and improved patient outcomes, particularly for those with autoimmune conditions and multiple sclerosis.
A New Era of Ethical Leadership

Sep 8, 2023 | pharmexec.com | Lisa Henderson

With the rise of artificial intelligence (AI) and other emerging technologies, professionals are facing unprecedented ethical dilemmas. The possibilities and perils of these advancements are blurring the line between right and wrong, leaving employees in need of guidance to make the right decision. The stakes have never been higher and require ethical leadership that champions technological development while remaining grounded in moral values. Lisa LeCointe-Cephas embodies this kind of leadership.